A major early-career grant co-sponsored by the Lung Cancer Foundation of America (LCFA) and the International Association for the Study of Lung Cancer (IASLC) to drive translational studies in thoracic oncology. This program provides $200,000 over two years to empower outstanding young investigators to pursue innovative projects with near-term potential to improve lung cancer patient care. By funding high-impact ideas across disciplines, the grant accelerates the bridge from laboratory discoveries to clinical applications in lung cancer.
Eligibility Criteria:
- Applicant must be an early-career scientist or clinician (e.g. within 7 years of first faculty appointment) with a demonstrated commitment to lung cancer research.
- Must be a member of IASLC in good standing. (Researchers from any country are eligible, provided they join IASLC.)
- The research proposal should be translational in nature – i.e., focused on applying scientific findings to improve lung cancer detection, treatment, or outcomes. Projects with clear relevance to patient care and immediate impact on lung cancer patients are strongly encouraged.
Funding Details:
- Grant Amount: $200,000 USD total, disbursed as $100,000 per year for 2 years.
- Grant Duration: 24 months (start date anticipated in mid-2026). Continued funding for the second year is contingent on adequate progress in year 1.
- Use of Funds: Supports salaries, supplies, and other research costs. This significant award is intended to enable the awardee to establish a lab or generate the robust preliminary data needed for larger grants. Indirect costs are not covered.
Deadline:
- January 8, 2026 – Application portal closes on this date (for the 2025–2026 grant cycle).
- The application window is currently open (Oct 15, 2025 – Jan 8, 2026). Awardees will be notified mid-2026 after a competitive peer-review and are expected to begin projects later in 2026.
Where to go for further information: